Anindya Bhattacharya

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11472287/publications.pdf

Version: 2024-02-01

69 papers	3,509 citations	109137 35 h-index	143772 57 g-index
69 all docs	69 docs citations	69 times ranked	4928 citing authors

#	Article	IF	Citations
1	PolymiRTS Database 3.0: linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways. Nucleic Acids Research, 2014, 42, D86-D91.	6.5	308
2	The microglial ATPâ€gated ion channel P2X7 as a CNS drug target. Glia, 2016, 64, 1772-1787.	2.5	155
3	Pharmacological characterization of a novel centrally permeable <scp>P2X7</scp> receptor antagonist: <scp>JNJ</scp>â€47965567. British Journal of Pharmacology, 2013, 170, 624-640.	2.7	148
4	Critical dataâ€based reâ€evaluation of minocycline as a putative specific microglia inhibitor. Glia, 2016, 64, 1788-1794.	2.5	137
5	Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy. Journal of Neuroscience, 2016, 36, 5920-5932.	1.7	127
6	The role of microglial P2X7: modulation of cell death and cytokine release. Journal of Neuroinflammation, 2017, 14, 135.	3.1	126
7	Role of neuro-immunological factors in the pathophysiology of mood disorders. Psychopharmacology, 2016, 233, 1623-1636.	1.5	120
8	PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Research, 2012, 40, D216-D221.	6.5	116
9	SomamiR 2.0: a database of cancer somatic mutations altering microRNAâ€“ceRNA interactions. Nucleic Acids Research, 2016, 44, D1005-D1010.	6.5	115
10	Ageâ€associated micro<scp>RNA</scp> expression in human peripheral blood is associated with allâ€cause mortality and ageâ€related traits. Aging Cell, 2018, 17, e12687.	3.0	114
11	microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus. Scientific Reports, 2015, 5, 17486.	1.6	98
12	SomamiR: a database for somatic mutations impacting microRNA function in cancer. Nucleic Acids Research, 2013, 41, D977-D982.	6.5	87
13	Recent Advances in CNS P2X7 Physiology and Pharmacology: Focus on Neuropsychiatric Disorders. Frontiers in Pharmacology, 2018, 9, 30.	1.6	86
14	Emerging role of the P2X7-NLRP3-IL1Î² pathway in mood disorders. Psychoneuroendocrinology, 2018, 98, 95-100.	1.3	78
15	Preclinical Evaluation of a P2X7 Receptorâ€“Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. Journal of Nuclear Medicine, 2016, 57, 1436-1441.	2.8	77
16	Pharmacology and Antitussive Efficacy of 4-(3-Trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic Acid (5-Trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a Transient Receptor Potential Vanilloid 1 Antagonist in Guinea Pigs. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 665-674.	1.3	73
17	RNA sequencing analysis reveals quiescent microglia isolation methods from postnatal mouse brains and limitations of BV2 cells. Journal of Neuroinflammation, 2018, 15, 153.	3.1	69
18	Pharmacology of a Novel Central Nervous Systemâ€“Penetrant P2X7 Antagonist JNJ-42253432. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 628-641.	1.3	67

#	Article	IF	Citations
19	The evolution of P2X7 antagonists with a focus on CNS indications. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3838-3845.	1.0	66
20	P2X7 Antagonists as Potential Therapeutic Agents for the Treatment of CNS Disorders. Progress in Medicinal Chemistry, 2014, 53, 65-100.	4.1	59
21	A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1<i>H</i>-[1,2,3]triazolo[4,5-<i>c</i>]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate. Journal of Medicinal Chemistry, 2018, 61, 207-223.	2.9	58
22	P2X7 receptor antagonism reduces the severity of spontaneous seizures in a chronic model of temporal lobe epilepsy. Neuropharmacology, 2016, 105, 175-185.	2.0	57
23	Divisive Correlation Clustering Algorithm (DCCA) for grouping of genes: detecting varying patterns in expression profiles. Bioinformatics, 2008, 24, 1359-1366.	1.8	56
24	Dissecting the Roles of MicroRNAs in Coronary Heart Disease via Integrative Genomic Analyses. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1011-1021.	1.1	53
25	Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. Neuropsychopharmacology, 2018, 43, 2586-2596.	2.8	52
26	4-Methyl-6,7-dihydro-4<i>H</i>-triazolo[4,5-<i>c</i>]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate. Journal of Medicinal Chemistry, 2017, 60, 4559-4572.	2.9	51
27	PET Imaging of the P2X7 Ion Channel with a Novel Tracer [18F]JNJ-64413739 in a Rat Model of Neuroinflammation. Molecular Imaging and Biology, 2019, 21, 871-878.	1.3	50
28	Effects of P2X7 receptor antagonists on hypoxia-induced neonatal seizures in mice. Neuropharmacology, 2017, 116, 351-363.	2.0	44
29	Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. Journal of Psychopharmacology, 2018, 32, 1341-1350.	2.0	44
30	Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists. ACS Medicinal Chemistry Letters, 2015, 6, 671-676.	1.3	42
31	Role of Neuro-Immunological Factors in the Pathophysiology of Mood Disorders: Implications for Novel Therapeutics for Treatment Resistant Depression. Current Topics in Behavioral Neurosciences, 2016, 31, 339-356.	0.8	42
32	Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X₇ Antagonists. ACS Medicinal Chemistry Letters, 2013, 4, 419-422.	1.3	40
33	A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334. European Journal of Pharmacology, 2015, 765, 551-559.	1.7	40
34	Bi-correlation clustering algorithm for determining a set of co-regulated genes. Bioinformatics, 2009, 25, 2795-2801.	1.8	38
35	Integrative Analysis of Somatic Mutations Altering MicroRNA Targeting in Cancer Genomes. PLoS ONE, 2012, 7, e47137.	1.1	37
36	The role of P2X7 receptors in a rodent PCP-induced schizophrenia model. Scientific Reports, 2016, 6, 36680.	1.6	36

#	Article	IF	Citations
37	Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of ¹⁸F-JNJ-64413739, a PET Radioligand for P2X7 Receptors. Journal of Nuclear Medicine, 2019, 60, 1154-1159.	2.8	36
38	Identification of (<i>R</i>)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4< (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor. Journal of Medicinal Chemistry, 2016, 59, 8535-8548.	2.9	35
39	miR2GO: comparative functional analysis for microRNAs. Bioinformatics, 2015, 31, 2403-2405.	1.8	32
40	miRNA Biogenesis Enzyme Drosha Is Required for Vascular Smooth Muscle Cell Survival. PLoS ONE, 2013, 8, e60888.	1.1	31
41	Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3157-3163.	1.0	30
42	Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development. Frontiers in Pharmacology, 2019, 10, 840.	1.6	25
43	Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-<i>a</i>]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain. ACS Chemical Neuroscience, 2016, 7, 490-497.	1.7	23
44	A GPU-accelerated algorithm for biclustering analysis and detection of condition-dependent coexpression network modules. Scientific Reports, 2017, 7, 4162.	1.6	22
45	Average correlation clustering algorithm (ACCA) for grouping of co-regulated genes with similar pattern of variation in their expression values. Journal of Biomedical Informatics, 2010, 43, 560-568.	2.5	20
46	Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3- a]pyrazin-8(5 H)-one P2X7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 257-261.	1.0	20
47	Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1G93A female mice. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	19
48	The Physiology, Pharmacology and Future of P2X7 as An Analgesic Drug Target: Hype or Promise?. Current Pharmaceutical Biotechnology, 2011, 12, 1698-1706.	0.9	19
49	Pharmacological and functional characterization of bradykinin B2 receptor in human prostate. European Journal of Pharmacology, 2004, 504, 155-167.	1.7	18
50	Identification and synthesis of 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives as TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 40-46.	1.0	18
51	P2X7 receptor antagonists for the treatment of systemic inflammatory disorders. Progress in Medicinal Chemistry, 2020, 59, 63-99.	4.1	18
52	Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders. Neuropsychopharmacology, 2020, 45, 234-235.	2.8	18
53	Systematic Analysis of microRNA Targeting Impacted by Small Insertions and Deletions in Human Genome. PLoS ONE, 2012, 7, e46176.	1.1	18
54	Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist. European Journal of Pharmacology, 2011, 663, 40-50.	1.7	17

#	Article	IF	Citations
55	Substituted 5,6-(Dihydropyrido[3,4-<i>d</i>]pyrimidin-7(8<i>H</i>)-yl)-methanones as P2X7 Antagonists. ACS Chemical Neuroscience, 2016, 7, 498-504.	1.7	17
56	Epigenome-wide association study of DNA methylation and microRNA expression highlights novel pathways for human complex traits. Epigenetics, 2020, 15, 183-198.	1.3	15
57	Systematic Prediction of the Impacts of Mutations in MicroRNA Seed Sequences. Journal of Integrative Bioinformatics, 2017, 14, .	1.0	14
58	Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepines as novel TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7137-7141.	1.0	10
59	OCDD: an obesity and co-morbid disease database. BioData Mining, 2017, 10, 33.	2.2	10
60	Isolation and Culture of Astrocytes from Postnatal and Adult Mouse Brains. Methods in Molecular Biology, 2019, 1938, 37-47.	0.4	10
61	Pharmacological characterization of canine bradykinin receptors in prostatic culture and in isolated prostate. British Journal of Pharmacology, 2004, 142, 297-304.	2.7	9
62	The discovery and preclinical characterization of 6-chloro- N -(2-(4,4-difluoropiperidin-1-yl)-2-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinoline-5-carboxamide based P2X7 antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4781-4784.	1.0	8
63	Knowledge-based analysis of functional impacts of mutations in microRNA seed regions. Journal of Biosciences, 2015, 40, 791-798.	0.5	7
64	Deletion of DGCR8 in VSMCs of adult mice results in loss of vascular reactivity, reduced blood pressure and neointima formation. Scientific Reports, 2018, 8, 1468.	1.6	7
65	1,2-Diamino-ethane-substituted-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepines as TRPV1 antagonists with improved properties. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7142-7146.	1.0	6
66	Comparative Analysis of Clustering and Biclustering Algorithms for Grouping of Genes: Co-Function and Co-Regulation. Current Bioinformatics, 2012, 7, 63-76.	0.7	4
67	Functional Analysis of Genetic Variants and Somatic Mutations Impacting MicroRNA-Target Recognition: Bioinformatics Resources. Methods in Molecular Biology, 2019, 1970, 101-120.	0.4	4
68	Effect of neurokinins on canine prostate cell physiology. Prostate, 2005, 63, 358-368.	1.2	3
69	Concepts of relative sample outlier (RSO) and weighted sample similarity (WSS) for improving performance of clustering genes: co-function and co-regulation. International Journal of Data Mining and Bioinformatics, 2015, 11, 314.	0.1	0